CHD Bioscience awarded patent for composition of matter of antimicrobial product line
Wednesday April 24, 2013FORT COLLINS - CHD Bioscience Inc. announced it has received a patent from the U.S. Patent Office for the composition of matter for CHD's family of antimicrobial products.
"The issuance of this patent represents an important milestone for CHD and the team," said Michael K. Handley, CHD's CEO.
"It demonstrates the novelty of our antimicrobial products and builds a foundation for a strong intellectual property portfolio."
CHD, a development-stage life science company, is working to commercialize a new class of antimicrobial products that have demonstrated, both in vitro and in vivo, the ability to safely eliminate a broad range of bacteria, viruses and other pathogens without harming human tissue.
CHD's first product, VERIOX, is being developed for a wide variety of markets including skin surface disinfection, medical device coatings and advanced wound care applications.
The research that created VERIOX bnegan in 2008 under the name CHATA Biosystems Inc., which was sold in 2011 and subsequently became CHD Bioscience.
For more information, visit www.chdbioscience.com.